阿法骨化醇对56例原发性骨质疏松症的疗效观察  

Therapeutic effect of alfacalcidol on 56 cases of primary senile osteoporosis

作　　者：陈培森[1] 金黎菊 刘小岭[1] 王慧华[1] 

机构地区：[1]上海市宝山区长江路社区卫生服务中心,上海200435

出　　处：《上海医药》2013年第9期19-20,23,共3页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:观察阿法骨化醇(1α-羟维生素D3)对老年性、绝经后性骨质疏松症的治疗。方法:选择112例50岁以上老年原发性骨质疏松症患者随机分为两组,每组各56例;对照组患者每天口服钙剂治疗,治疗组在此基础上加用阿法骨化醇片治疗。结果:两组治疗前脚踝骨密度比较差异无统计学意义(P>0.05)。治疗后,两组指标都有明显增加,但治疗组患者脚踝骨密度较对照组均明显增加,差异有统计学意义(P<0.05)。治疗组的疼痛改善总有效率为80.4%,而对照组为37.5%,治疗组明显好于对照组(P<0.05)。结论:阿法骨化醇治疗原发性骨质疏松症能够有效提高脚踝骨密度,缓解疼痛症状。Objective： To explore the therapeutic efficacy of alfacalcidol on primary senile osteoporosis. Methods： One hndred and twelve elderly patients with primary osteoporosis were selected and randomly divided into two groups, 56 patients each. Patients in the control group were treated with basic daily oral calcium, while alfacalcidol therapy was additionally given in the treatment group besides the basic treatment. Results： Before the treatment, no statistically significant difference was found in the bone mineral density between these two groups （P〉0.05）. After the treatment, the indicators of patients in these two groups were significantly improved, but the bone mineral density in the treatment group were significantly higher than that in the control group （P〈0.05）. The total response rate of pain improvement was 80. 4% in the treatment group vs 37.5% in the control group, and the treatment group was superior to the control group （P〈0.05）. Conclusion： Alfacalcidol in the treatment of primary senile osteoporosis can effectively improve the bone mineral density and relieve the pain.

关 键 词：阿法骨化醇 老年骨质疏松症 脚踝骨密度 疼痛 

分 类 号：R580[医药卫生—内分泌]